EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Endocannabinoid cerebrospinal fluid levels in migraine and its relation to symptoms of depression

Aster V E Harder iD, Xinyu Di, Wendy M Winter, Bingshu He, Robin M Van Dongen iD, Gerrit L J Onderwater, Erik W Van Zwet, Elke H J Krekels, Isabelle Kohler, Michel D Ferrari iD, Amy C Harms, Arn M J M Van Den Maagdenberg iD und 2 weitere

Cephalalgia · 2026-07 · 46 (7)

DOI: 10.1177/03331024261451250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, online erschienen am 10.07.2026. Verfasst von Aster V E Harder und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Endocannabinoids, Migraine Disorders, Depression. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw, FP7 Ideas: European Research Council, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Disruption of the endocannabinoid system has been implicated in both migraine and depression, which are frequently comorbid in patients. Nevertheless, supporting evidence for this hypothesis is limited. Hence, we investigated whether the endocannabinoid system is disrupted in interictal migraine patients and whether confounding factors were of influence.

Methods

To this end, we measured the levels of endocannabinoids N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), and the endocannabinoid analogue docosahexaenoylethanolamine (DHEA) in the cerebrospinal fluid (CSF), obtained from 194 individuals with episodic migraine between attacks (97 migraine with aura and 97 migraine without aura individuals) and from 94 healthy volunteers, using micro-liquid chromatography – tandem mass spectrometry (micro-LC-MS/MS). Groups were age- and sex-matched. Timing and processing of sampling was protocolized. Multivariate linear regression analyses for log 10 -transformed endocannabinoid concentrations were performed to compare groups. Covariates that were included were sex, age, BMI, substance use and depressive symptoms.

Results

No differences were detected between individuals with migraine with or without aura and healthy controls in the CSF for AEA ( p = 0.46, p = 0.08), 2-AG ( p = 0.46, p = 0.90) and DHEA ( p = 0.58, p = 0.79), respectively. For 2-AG, levels were, however, positively correlated with depressive symptoms (β = 0.053; 95% CI: 0.014 to 0.093, p = 0.008).

Conclusion

CSF endocannabinoids (AEA, 2-AG, and DHEA) may not serve as effective biomarkers for distinguishing interictal episodic migraine patients from controls. Instead, CSF levels of 2-AG are linked to depressive symptoms, shedding further light on the relevance of endocannabinoids in patients with migraine and depression. This study highlights the intricate nature of the endocannabinoid system concerning episodic migraine and confounding factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EndocannabinoidsMigraine DisordersDepressionHumansFemaleAdultMaleMiddle AgedBiomarkers

Stichwörter der Autor:innen

cerebrospinal fluiddepressionendocannabinoidsmetabolomicsmigraine

Substanzen

EndocannabinoidsBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Analytical BioSciences and Metabolomics, Leiden Academic Center for Drug Research, Leiden, The Netherlands.
  • Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
  • Division of Systems Pharmacology and Pharmacy, Leiden Academic Center for Drug Research, Leiden, The Netherlands.
  • Division of Bioanalytical Chemistry, Amsterdam Institute of Molecular Life Sciences, Amsterdam, The Netherlands.

ORCID-Profile: Aster V E Harder, Robin M Van Dongen, Michel D Ferrari, Arn M J M Van Den Maagdenberg, Gisela M Terwindt

Förderung

  • ZonMw
  • FP7 Ideas: European Research Council
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Harder, A. V. E., Di, X., Winter, W. M., He, B., Van Dongen, R. M., Onderwater, G. L. J., Van Zwet, E. W., Krekels, E. H. J., Kohler, I., Ferrari, M. D., Harms, A. C., Van Den Maagdenberg, A. M. J. M., Hankemeier, T., & Terwindt, G. M. (2026). Endocannabinoid cerebrospinal fluid levels in migraine and its relation to symptoms of depression. Cephalalgia, 46(7). https://doi.org/10.1177/03331024261451250

Vancouver

Harder AVE, Di X, Winter WM, He B, Van Dongen RM, Onderwater GLJ, et al. Endocannabinoid cerebrospinal fluid levels in migraine and its relation to symptoms of depression. Cephalalgia. 2026;46(7). doi:10.1177/03331024261451250

BibTeX
@article{Harder2026,
  author = {Harder, Aster V E and Di, Xinyu and Winter, Wendy M and He, Bingshu and Van Dongen, Robin M and Onderwater, Gerrit L J and Van Zwet, Erik W and Krekels, Elke H J and Kohler, Isabelle and Ferrari, Michel D and Harms, Amy C and Van Den Maagdenberg, Arn M J M and Hankemeier, Thomas and Terwindt, Gisela M},
  title = {Endocannabinoid cerebrospinal fluid levels in migraine and its relation to symptoms of depression},
  journal = {Cephalalgia},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1177/03331024261451250}
}
Kostenlos starten →